重组人干扰素α-2a凝胶预防尖锐湿疣复发的随机双盲多中心临床研究  

Double-blind randomized multicenter controlled clinical trial of recombinant interferon α-2a gel versus placebo in prevention of condyloma acuminata relapse

作　　者：汪科[1] 韩钢文[1] 郑和义[2] 李福秋[3] 白义杰[4] 徐金华[5] 朱学骏[1] 

机构地区：[1]北京大学第一医院皮肤性病科,北京100034 [2]中国医学科学院,中国协和医科大学北京协和医院,北京100730 [3]吉林大学第二医院,吉林长春130041 [4]辽宁省人民医院,辽宁沈阳110015 [5]复旦大学附属华山医院,上海200040

出　　处：《中国临床药理学杂志》2006年第2期109-111,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价重组人干扰素α-2a凝胶(抗尖锐湿疣凝胶)预防尖锐湿疣复发的有效性和安全性。方法与安慰剂对照,尖锐湿疣患者经激光、冷冻或电灼清除疣体后,每日外用药物4次,疗程8周,再随访至第20周。共入选尖锐湿疣患者154例。结果在用药第2,4,8,12,16,20周,试验组复发率明显低于安慰剂组,统计学上有显著性差异。结论重组人干扰素α-2a凝胶对尖锐湿疣治愈后、预防复发的疗效肯定,耐受性好。Objective To study the efficacy and safety of recombinant interferon α -2a gel in prevention of condyloma acuminata relapse. Methods Recombinant interferon α -2a gel or placebo was applied 4 times daily for 8 weeks after condyloma acuminata was clinically cleared by laser, cryotheropy or electrodesiccation, both treatment groups were followed up for 12 weeks. Results One hundred and fifty four cases were involved. The results showed that relapse rates of recombinant interferon α-2a gel were lower than that of placebo at week 2,4,8,12,16,20. The relapse rates between two groups had significant statistic differences. Conclusion Recombinant interferon α -2a gel is a topical drug with good efficacy, safety and tolerability in prevention of condyloma acuminata relapse.

关 键 词：重组人干扰素Α-2A 尖锐湿疣 复发 

分 类 号：R752.53[医药卫生—皮肤病学与性病学] R986[医药卫生—临床医学]